Condition: T2DM (Type 2 Diabetes Mellitus) · Sponsor: Shenzhen HighTide Biopharmaceutical Ltd.
The goal of this clinical study is to evaluate the efficacy and safety of Berberine Ursodeoxycholate (HTD1801) compared to placebo in patients with type 2 diabetes, inadequately controlled with diet and exercise alone.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Xuancheng People's Hospital | Xuancheng, Anhui, China | — |
| Beijing Pinggu Hospital | Beijing, Beijing Municipality, China | — |
| Fuwai Hospital, CAMS & PUMC | Beijing, Beijing Municipality, China | — |
| Peking Union Medical College Hospital | Beijing, Beijing Municipality, China | — |
| Peking University People's Hospital | Beijing, Beijing Municipality, China | — |
| Chongqing University Three Gorges Hospital | Chongqing, Chongqing Municipality, China | — |
| Nanfang Hospital, Southern Medical University | Guangzhou, Guangdong, China | — |
| Huizhou Municipal Central Hospital | Huizhou, Guangdong, China | — |
| Shenzhen People's Hospital | Shenzhen, Guangdong, China | — |
| Liuzhou People's Hospital | Liuzhou, Guangxi, China | — |
| Cangzhou Central Hospital | Cangzhou, Hebei, China | — |
| Handan First Hospital | Handan, Hebei, China | — |
+ 44 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.